Table 3 Main toxicities associated with imatinib mesylate and reasons for discontinuation, metastatic patients excluded.
From: Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor
Patients N (%) | ||
|---|---|---|
Variable | All grades | Grade 3–4 |
Edema/fluid retention | 28 (48) | 1 (2) |
Fatigue | 29 (50) | 1 (2) |
Nausea | 20 (34) | |
Skin rash/dermatitis | 7 (12) | 2 (3) |
Other* | 15 (26) | 3 (5) |
Treatment status | ||
Continued on IM | 20 (34) | |
Stopped IM | 38 (66) | |
Reason for stopping | ||
Progression | 1 (2) | |
Toxicity | 7 (12) | |
Surgery | 10 (17) | |
Patient choice | 14 (24) | |
Physician decision | 5 (9) | |
Other tumor | 1 (2) | |
